|OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines|
W Zhang, RW Moskowitz, G Nuki, S Abramson, RD Altman, N Arden, ...
Osteoarthritis and cartilage 16 (2), 137-162, 2008
|B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large …|
M Snuderl, OK Kolman, YB Chen, JJ Hsu, AM Ackerman, P Dal Cin, ...
The American journal of surgical pathology 34 (3), 327, 2010
AD Zelenetz, JS Abramson, RH Advani, CB Andreadis, JC Byrd, ...
Journal of the National Comprehensive Cancer Network 8 (3), 288-334, 2010
|Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis|
AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ...
Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014
|The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma|
P Juszczynski, J Ouyang, S Monti, SJ Rodig, K Takeyama, J Abramson, ...
Proceedings of the National Academy of Sciences 104 (32), 13134-13139, 2007
|Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL|
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine, 2018
|Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach|
JS Abramson, MA Shipp
Blood 106 (4), 1164-1174, 2005
|Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma|
JS Abramson, M Hellmann, JA Barnes, P Hammerman, C Toomey, ...
Cancer 116 (18), 4283-4290, 2010
|Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity|
BL Lampson, SN Kasar, TR Matos, EA Morgan, L Rassenti, MS Davids, ...
Blood, The Journal of the American Society of Hematology 128 (2), 195-203, 2016
|Evaluating the impact of the humanities in medical education|
AW Schwartz, JS Abramson, I Wojnowich, R Accordino, EJ Ronan, ...
Mount Sinai Journal of Medicine: A Journal of Translational and Personalized …, 2009
|Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)|
SJ Rodig, JS Abramson, GS Pinkus, SP Treon, DM Dorfman, HY Dong, ...
Clinical Cancer Research 12 (23), 7174-7179, 2006
|Diagnosis and management of Castleman disease|
JD Soumerai, AR Sohani, JS Abramson
Cancer control 21 (4), 266-278, 2014
|Non-Hodgkin’s lymphomas, version 4.2014|
AD Zelenetz, LI Gordon, WG Wierda, JS Abramson, RH Advani, ...
Journal of the National Comprehensive Cancer Network 12 (9), 1282-1303, 2014
|Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis|
JA Barnes, AS Lacasce, Y Feng, CE Toomey, D Neuberg, JS Michaelson, ...
Annals of Oncology 22 (8), 1859-1864, 2011
|Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303|
WH Wilson, J Sin-Ho, BN Pitcher, ED Hsi, J Friedberg, B Cheson, ...
Blood, The Journal of the American Society of Hematology 128 (22), 469-469, 2016
|End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma|
JA Barnes, AS LaCasce, K Zukotynski, D Israel, Y Feng, D Neuberg, ...
Annals of oncology 22 (4), 910-915, 2011
|International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)|
A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ...
Annals of Oncology 28 (7), 1436-1447, 2017
|Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.|
JS Abramson, LI Gordon, ML Palomba, MA Lunning, JE Arnason, ...
Journal of clinical oncology 36 (15_suppl), 7505-7505, 2018
|Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy|
JS Abramson, T Feldman, AR Kroll-Desrosiers, LS Muffly, E Winer, ...
Annals of oncology 25 (11), 2211-2217, 2014
|T‐cell/histiocyte‐rich B‐cell lymphoma: Biology, diagnosis, and management|
The Oncologist 11 (4), 384-392, 2006